Evercare Sets Standard with Molecular Imaging System

Olaoluwakitan Babatunde

Evercare Hospital, Lekki, a state-of-the-art medical facility located in Lagos, has raised the bar in clinical excellence and diagnostic versatility with the procurement and installation of the GE SPECT-CT 870 DR, a premium hybrid molecular imaging system developed by GE Healthcare.

One of five nuclear medicine systems in the 800 series, the GE SPECT-CT 870 DR machine puts into practice everything that the global medical technology and digital solutions innovator has learned over the course of 20 years by bringing the latest in SPECT/CT advancements to a wider range of clinical environments.

“At Evercare Hospital, quality patient care is our goal. And it starts with making an accurate diagnosis. That is why we are constantly investing in technologies and solutions—like the GE SPECT-CT 870 DR—that increase our diagnostic capabilities and lead to better patient outcomes. This machine provides shorter, more tolerable exams for greater patient comfort. Also, it is able to detect small lesions, allowing us to diagnose diseases faster and provide better care,” said Rajeev Bhandari, Chief Executive Officer of Evercare.

Eyong Ebai, GE Healthcare’s General Manager for Sub-Saharan Africa said: “It is this ability to make visible what could normally be invisible that enables true discovery in nuclear medicine. Leading clinical discovery is about improving care for as many patients as possible. Everything we do is with the purpose of providing top private facilities like Evercare, as well as public hospitals, with the tools they need to go in search of true discovery. The GE SPECT-CT 870 DR reflects our continued commitment to helping improve quality, access and affordability of SPECT/CT, so they can continue in their work to change lives for the better.

“All our 800 Series SPECT-CT systems build on the success of the 600 Series with a collection of SPECT technology enhancements that add to the value of nuclear medicine. The GE SPECT-CT 870 DR is Digital Ready. The system’s modular design enables an in-field upgrade to a CZT-based technology from the current NaI/PMT detector design. Such investment protection allows hospitals that acquire the equipment future access to the latest digital technology to expand Nuclear Medicine applications and research opportunities, without a need to fully replace the hybrid system and also to facilitate capital planning.”